Investeringsforeningen IA Invest, Afdeling Furesø Globale Kvalitetsaktier – Prospekt, dokument med central information og tegningsblanket
Investeringsforeningen IA Invest har indledende tegningsperiode i følgende afdeling fra den 22. april til og med den 3. maj 2024:
| Afdeling | ISIN-kode | Tegningskurs (franco) |
| Furesø Globale Kvalitetsaktier | DK0062842217 | 100,20 |
Betalingsdag er den 8. maj 2024, og første handelsdag er den 14. maj 2024.
Prospekt, dokument med central information samt tegningsblanket er vedhæftet denne meddelelse.
For yderligere information henvises der til henholdsvis foreningens og afdelingens hjemmeside www.iainvest.dk og www.furesoekapital.dk.
Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til undertegnede på telefon 38 14 66 00.
Med venlig hilsen
Niels Erik Eberhard
Direktør
Vedhæftede filer
- IAI Prospekt_16-04-2024_clean inkl. SFDR
- IAI PRIIP KID Furesø 2024.04.16 DK0062842217
- IAI Tegningsblanket Furesø_clean
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer30.4.2024 00:40:00 CEST | Press release
Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapyTIVDAK is the first antibody-drug conjugate in this patient population to have positive overall survival data COPENHAGEN, Denmark; April 30, 2024 – Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This FDA action converts the September 2021 accelerated approval of TIVDAK to a full approval. TIVDAK is the first antibody-drug conjugate (ADC) with demonstrated overall survival data to be granted full FDA approval in this patient population. The approval is based on results from the global, randomized, Phase 3 innovaTV 301 clinical trial (NCT04697628), in which TIV
GOGL – 2024 AGM Results Notification29.4.2024 23:22:57 CEST | Press release
Golden Ocean Group Limited (the “Company”) advises that the 2024 Annual General Meeting of the Shareholders of the Company was held on April 29, 2024, at 16:30 hrs, at Hamilton Princess and Beach Club, 76 Pitts Bay Road, Hamilton HMCX, Bermuda. The audited consolidated financial statements for the Company for the year ended December 31, 2023 were presented to the Meeting. In addition, the following resolutions were passed: To set the maximum number of Directors to be not more than eight. To resolve that vacancies in the number of Directors be designated as casual vacancies and that the Board of Directors be authorized to fill such vacancies as and when it deems fit. To re-elect Ola Lorentzon as a Director of the Company. To re-elect John Fredriksen as a Director of the Company To re-elect James O’Shaughnessy as a Director of the Company. To re-elect Ben Mills as a Director of the Company. To re-elect Cato Stonex as a Director of the Company. To re-appoint PricewaterhouseCoopers AS as a
SFL - 2024 AGM Results Notification29.4.2024 22:16:00 CEST | Press release
SFL Corporation Ltd. (NYSE: SFL) (“SFL” or the “Company”) advises that the 2024 Annual General Meeting of the Company was held on April 29, 2024, at 9:45 hours at Hamilton Princess and Beach Club, 76 Pitts Bay Road, Hamilton HMCX, Bermuda. The audited consolidated financial statements for the Company for the year ended December 31, 2023, were presented to the Meeting. In addition, the following resolutions were passed: 1. To set the maximum number of Directors to be not more than eight. 2. To resolve that vacancies in the number of Directors be designated as casual vacancies and that the Board of Directors be authorised to fill such vacancies as and when it deems fit. 3. To re-elect Kathrine Fredriksen as a Director of the Company. 4. To re-elect Gary Vogel as a Director of the Company. 5. To re-elect Keesjan Cordia as a Director of the Company. 6. To re-elect James O’Shaughnessy as a Director of the Company. 7. To re-elect Ole Hjertaker as a Director of the Company. 8. To re-elect Wil
Nature’s Sunshine Recognized with Six Stevie Awards in the 2024 American Business Awards29.4.2024 22:05:00 CEST | Press release
LEHI, Utah, April 29, 2024 (GLOBE NEWSWIRE) -- Nature’s Sunshine Products (Nasdaq: NATR), a leading natural health and wellness company of premium-quality herbal and nutritional products, received six Stevies—including three Gold Stevie Awards—in the 2024 American Business Awards. Gold Stevie Awards Saving Energy – Celebrating Nature’s Sunshine’s transition to 100% solar power at our U.S. manufacturing facility and additional efforts to reduce energy usage through increased efficiencies.Marketing Campaign of the Year – Health, Fitness & Wellness – Acknowledging the launch of the Power Line—Power Beets, Power Greens and Power Meal—as one of the most successful product launch campaigns in the company’s history.Human Resources Team of the Year – Recognizing the Nature’s Sunshine Human Resources team for its efforts to engage employees, foster leadership development and develop an award-winning culture. In addition to the Gold Stevies, the company was also recognized with two Silver Stevie
Nokia Corporation: Repurchase of own shares on 29.04.202429.4.2024 21:41:21 CEST | Press release
Nokia Corporation Stock Exchange Release 29 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 29.04.2024 Espoo, Finland – On 29 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL385,3003.44CEUX--BATE--AQEU--TQEX--Total385,3003.44 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of